A type of immunotherapy where a patient's T-cells are modified to express a chimeric antigen receptor (CAR) that targets specific antigens on leukemia cells, used when standard treatments have failed.
Indicated for patients with relapsed or refractory leukemia who have not responded to standard therapies.
"Plan to initiate CAR T-cell therapy pending insurance authorization."
Used to document the intended use of CAR T-cell therapy in the treatment plan for eligible patients with refractory leukemia.
Common questions about using medical phrases in clinical documentation